nach oben

Erschienen in:

07.06.2017 | Main topic

Interventional treatment of the aortic valve

Current evidence

verfasst von: F. Jansen, MD, N. Werner, MD

Erschienen in: Herz | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Transcatheter aortic valve replacement (TAVR) has become a standard treatment for patients with severe, symptomatic aortic stenosis. Whereas its use was first limited to inoperable high-risk patients, recent studies demonstrated that TAVR was not inferior to standard surgical aortic valve replacement (SAVR) for intermediate-risk patients. Besides equivalent outcomes, the type and rates of complications differ between the two procedures. Here, we provide an overview of the latest randomized study results comparing TAVR with SAVR and describe possible future directions in transcatheter aortic valve treatment.

Lababidi Z (1983) Aortic balloon valvuloplasty. Am Heart J 106:751–752CrossRefPubMed

Cribier A, Eltchaninoff H, Bash A et al (2002) Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106:3006–3008CrossRefPubMed

Reinöhl J, Kaier K, Reinecke H et al (2015) Effect of availability of transcatheter aortic-valve replacement on clinical practice. N Engl J Med 373:2438–2447. doi:10.1056/NEJMoa1500893 CrossRefPubMed

Rodés-Cabau J, Webb JG, Cheung A et al (2010) Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 55:1080–1090. doi:10.1016/j.jacc.2009.12.014 CrossRefPubMed

Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299–308. doi:10.1161/CIRCULATIONAHA.110.946533 CrossRefPubMed

Thomas M, Schymik G, Walther T et al (2010) Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122:62–69. doi:10.1161/CIRCULATIONAHA.109.907402 CrossRefPubMed

Piazza N, Grube E, Gerckens U et al (2008) Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1‑year following CE mark approval. EuroIntervention 4:242–249CrossRefPubMed

Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597–1607. doi:10.1056/NEJMoa1008232 CrossRefPubMed

Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198. doi:10.1056/NEJMoa1103510 CrossRefPubMed

10.

Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620. doi:10.1056/NEJMoa1514616 CrossRefPubMed

11.

Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. doi:10.1056/NEJMoa1700456

12.

Kodali SK, Williams MR, Smith CR et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366:1686–1695. doi:10.1056/NEJMoa1200384 CrossRefPubMed

13.

Kapadia SR, Leon MB, Makkar RR et al (2015) 5‑year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385:2485–2491. doi:10.1016/S0140-6736(15)60290-2 CrossRefPubMed

14.

Mack MJ, Leon MB, Smith CR et al (2015) 5‑year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385:2477–2484. doi:10.1016/S0140-6736(15)60308-7 CrossRefPubMed

15.

Grube E, Laborde JC, Gerckens U et al (2006) Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 114:1616–1624. doi:10.1161/CIRCULATIONAHA.106.639450 CrossRefPubMed

16.

Adams DH, Popma JJ, Reardon MJ et al (2014) Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370:1790–1798. doi:10.1056/NEJMoa1400590 CrossRefPubMed

17.

Reardon MJ, Adams DH, Kleiman NS et al (2015) 2‑year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 66:113–121. doi:10.1016/j.jacc.2015.05.017 CrossRefPubMed

18.

Thourani VH, Kodali S, Makkar RR et al (2016) Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387:2218–2225. doi:10.1016/S0140-6736(16)30073-3 CrossRefPubMed

19.

Thyregod HGH, Steinbrüchel DA, Ihlemann N et al (2015) Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1‑year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 65:2184–2194. doi:10.1016/j.jacc.2015.03.014 CrossRefPubMed

20.

Søndergaard L, Steinbrüchel DA, Ihlemann N et al (2016) Two-year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers nordic aortic valve intervention randomized clinical trial. Circ Cardiovasc Interv 9:e003665. doi:10.1161/CIRCINTERVENTIONS.115.003665 CrossRefPubMed

21.

Bosmans J, Bleiziffer S, Gerckens U et al (2015) The incidence and predictors of early- and mid-term clinically relevant neurological events after transcatheter aortic valve replacement in real-world patients. J Am Coll Cardiol 66:209–217. doi:10.1016/j.jacc.2015.05.025 CrossRefPubMed

22.

Hamm CW, Arsalan M, Mack MJ (2016) The future of transcatheter aortic valve implantation. Eur Heart J 37:803–810. doi:10.1093/eurheartj/ehv574 CrossRefPubMed

23.

Kapadia SR, Kodali S, Makkar R et al (2017) Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol 69:367–377. doi:10.1016/j.jacc.2016.10.023 CrossRefPubMed

24.

Haussig S, Mangner N, Dwyer MG et al (2016) Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA 316:592–601. doi:10.1001/jama.2016.10302 CrossRefPubMed

25.

Van Mieghem NM, van Gils L, Ahmad H et al (2016) Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. EuroIntervention 12:499–507. doi:10.4244/EIJV12I4A84 CrossRefPubMed

26.

Lansky AJ, Schofer J, Tchetche D et al (2015) A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J 36:2070–2078. doi:10.1093/eurheartj/ehv191 CrossRefPubMed

27.

Lip GYH, Windecker S, Huber K et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35(45):3155–3179CrossRefPubMed

28.

Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ et al (2016) Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 9:1706–1717. doi:10.1016/j.jcin.2016.06.025 CrossRefPubMed

29.

Søndergaard L, Sawaya FJ (2017) Antithrombotic management after transcatheter aortic valve replacement: more questions than answers. JACC Cardiovasc Interv 10:75–78. doi:10.1016/j.jcin.2016.11.024 CrossRefPubMed

30.

Nazif TM, Dizon JM, Hahn RT et al (2015) Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv 8:60–69. doi:10.1016/j.jcin.2014.07.022 CrossRefPubMed

31.

Urena M, Mok M, Serra V et al (2012) Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol 60:1743–1752. doi:10.1016/j.jacc.2012.07.035 CrossRefPubMed

32.

Urena M, Hayek S, Cheema AN et al (2015) Arrhythmia burden in elderly patients with severe aortic stenosis as determined by continuous electrocardiographic recording: toward a better understanding of arrhythmic events after transcatheter aortic valve replacement. Circulation 131:469–477. doi:10.1161/CIRCULATIONAHA.114.011929 CrossRefPubMed

33.

Pasic M, Unbehaun A, Buz S et al (2015) Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc Interv 8:1–9. doi:10.1016/j.jcin.2014.07.020 CrossRefPubMed

34.

Ribeiro HB, Webb JG, Makkar RR et al (2013) Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 62:1552–1562. doi:10.1016/j.jacc.2013.07.040 CrossRefPubMed

35.

Roy DA, Schaefer U, Guetta V et al (2013) Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol 61:1577–1584. doi:10.1016/j.jacc.2013.01.018 CrossRefPubMed

36.

Wendt D, Kahlert P, Pasa S et al (2014) Transapical transcatheter aortic valve for severe aortic regurgitation: expanding the limits. JACC Cardiovasc Interv 7:1159–1167. doi:10.1016/j.jcin.2014.04.016 CrossRefPubMed

37.

Azadani AN, Tseng EE (2011) Transcatheter heart valves for failing bioprostheses: state-of-the-art review of valve-in-valve implantation. Circ Cardiovasc Interv 4:621–628. doi:10.1161/CIRCINTERVENTIONS.111.964478 CrossRefPubMed

38.

Dvir D, Webb J, Brecker S et al (2012) Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation 126:2335–2344. doi:10.1161/CIRCULATIONAHA.112.104505 CrossRefPubMed

Titel: Interventional treatment of the aortic valve
Current evidence
verfasst von: F. Jansen, MD
N. Werner, MD
Publikationsdatum: 07.06.2017
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 6/2017
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-017-4585-y

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Interventional treatment of the aortic valve

Current evidence

Abstract

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Aortenklappe

CME: Diagnostik und Therapie von Fettstoffwechselstörungen

Kardioprotektion über den Arm?

Chirurgische Therapie der Aortenklappenstenose

Fractional flow reserve derived by coronary computed tomography angiography

Role of nifedipine and hydrochlorothiazide in MAPK activation and vascular smooth muscle cell proliferation and apoptosis

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie